Diametric Capital LP Makes New $252,000 Investment in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Diametric Capital LP purchased a new stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 31,782 shares of the company’s stock, valued at approximately $252,000.

A number of other institutional investors also recently modified their holdings of the business. Intech Investment Management LLC bought a new position in Amneal Pharmaceuticals in the third quarter valued at about $307,000. Charles Schwab Investment Management Inc. boosted its stake in shares of Amneal Pharmaceuticals by 16.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,404,883 shares of the company’s stock valued at $11,689,000 after purchasing an additional 202,863 shares in the last quarter. FMR LLC grew its holdings in shares of Amneal Pharmaceuticals by 25.9% during the 3rd quarter. FMR LLC now owns 203,510 shares of the company’s stock valued at $1,693,000 after purchasing an additional 41,882 shares during the last quarter. Walleye Capital LLC acquired a new position in Amneal Pharmaceuticals during the 3rd quarter worth approximately $1,095,000. Finally, Polar Asset Management Partners Inc. lifted its stake in Amneal Pharmaceuticals by 122.5% in the 3rd quarter. Polar Asset Management Partners Inc. now owns 393,000 shares of the company’s stock valued at $3,270,000 after purchasing an additional 216,400 shares during the last quarter. Institutional investors and hedge funds own 31.82% of the company’s stock.

Amneal Pharmaceuticals Price Performance

Amneal Pharmaceuticals stock opened at $8.23 on Wednesday. The stock’s 50 day moving average is $8.41 and its 200 day moving average is $8.37. Amneal Pharmaceuticals, Inc. has a one year low of $5.18 and a one year high of $9.48. The firm has a market cap of $2.55 billion, a P/E ratio of -12.10 and a beta of 1.05.

Amneal Pharmaceuticals (NASDAQ:AMRX) last posted its quarterly earnings data on Friday, February 28th. The company reported $0.12 EPS for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.03). The firm had revenue of $730.52 million during the quarter, compared to the consensus estimate of $708.21 million. Amneal Pharmaceuticals had a negative net margin of 6.88% and a negative return on equity of 346.26%. During the same period in the prior year, the company posted $0.14 earnings per share. Equities analysts anticipate that Amneal Pharmaceuticals, Inc. will post 0.53 earnings per share for the current fiscal year.

Insider Transactions at Amneal Pharmaceuticals

In related news, major shareholder Tushar Bhikhubhai Patel sold 5,000,000 shares of the business’s stock in a transaction on Friday, March 14th. The shares were sold at an average price of $8.35, for a total transaction of $41,750,000.00. Following the transaction, the insider now owns 48,578,209 shares in the company, valued at $405,628,045.15. The trade was a 9.33 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Gautam Patel sold 17,410 shares of the firm’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $8.01, for a total transaction of $139,454.10. Following the completion of the sale, the director now owns 2,031,476 shares of the company’s stock, valued at $16,272,122.76. The trade was a 0.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 5,240,000 shares of company stock valued at $43,754,000. Corporate insiders own 26.56% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on AMRX. StockNews.com downgraded shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, December 19th. Barclays upped their target price on Amneal Pharmaceuticals from $10.00 to $11.00 and gave the stock an “overweight” rating in a report on Monday, March 3rd. Finally, JPMorgan Chase & Co. raised Amneal Pharmaceuticals from a “neutral” rating to an “overweight” rating and lifted their price target for the company from $9.00 to $12.00 in a research note on Monday, February 24th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $10.80.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.